赖诺普利联合羟苯磺酸钙治疗糖尿病肾病的临床观察

赖诺普利联合羟苯磺酸钙治疗糖尿病肾病的临床观察
崔凤云;石振东
【期刊名称】《实用药物与临床》
【年(卷),期】2012(15)5
【摘要】目的观察赖诺普利联合羟苯磺酸钙治疗糖尿病肾病的临床疗效及安全性.方法选择32例糖尿病肾病患者,随机分为实验组(18例)、对照组(14例).对照组单用羟苯磺酸钙,实验组在此基础上加用赖诺普利.降糖药根据患者具体情况应用胰岛素皮下注射或口服降糖药治疗,各组疗程均为8周.疗程结束后检测并比较两组患者24 h尿白蛋白排泄率(24 h-UAER)、血肌酐(Scr)及尿素氮(BUN)等指标.结果实验组、对照组总有效率分别为94.5%、71.4%,差异有统计学意义(P<0.05).治疗后,实验组的24 h-UAER、Scr、BUN较对照组下降明显(P<0.05).结论赖诺普利联合羟苯磺酸钙治疗糖尿病肾病疗效确切,且无明显不良反应.%Objective To observe the efficacy and safety of lisinopril combined with calcium dobesilate on diabetic nephropathy. Methods 32 patients with diabetic nephropathy were randomly divided into the experiment group ( n = 18 )and control group( n = 14 ),patients in control group only used calcium dobesilate,experiment group used calcium dobesilate combined with lisinopril. Insulin subcutaneous injection or oral hypoglycemic drug treatment were given according to specific situation of patients, and the treatment period was 8 weeks. The 24 h urinary albumin excretion rate ( 24 h-UAER ),serum creatinine( Scr )and blood urea nitrogen( BUN )were recorded. Results The total effective rates of experimental group and
control group were 94. 5% and 71. 4% respectively( P <0. 05 ). After treatment, The 24 h-UAER,Scr,BUN of experiment group decreased more significantly than those of control group( P <0. 05 ). Conclusion The efficacy of lisinopril combined with calcium dobesilate on diabetic nephropathy is accurate without obvious adverse reaction.
【总页数】2页(P312-313)
【作者】崔凤云;石振东
【作者单位】沈阳医学院附属铁法煤业集团总医院内分泌科,辽宁,铁岭,112700;沈阳医学院附属铁法煤业集团总医院VIP病房,辽宁,铁岭,112700
【正文语种】中文
【相关文献】
1.坎地沙坦联合赖诺普利治疗糖尿病肾病蛋白尿的临床观察 [J], 吴康祺;梁思爱
2.前列地尔联合赖诺普利治疗早期糖尿病肾病的临床观察 [J], 王旭红
3.前列地尔联合赖诺普利治疗早期2型糖尿病肾病的临床观察 [J], 厉东亚
4.疏血通联合赖诺普利治疗糖尿病肾病的临床观察 [J], 刘美霞;周成梅
5.羟苯磺酸钙联合氯沙坦钾治疗糖尿病肾病蛋白尿的临床观察 [J], 曲铎
因版权原因，仅展示原文概要，查看原文内容请购买。